Abstract
One hundred seventeen postmenopausal advanced breast cancer patients previously untreated with chemotherapy were randomized to receive: cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), CMF and tamoxifen (TMX), and CMF and medroxyprogesterone (MAP). Treatments B and C induced a greater proportion of responses than treatment A. No effect was identified on the number of complete responses. After treatment failure, patients from groups A and C received Adriamycin (doxorubicin) (ADX) vincristine (VCR), and TMX and patients from group B received ADM, VCR, and MAP. No differences were found between the branches in the response rates to the second protocol. Responders to both treatments had a longer survival experience than nonresponders or responders to only one of the treatments. Survival was independent of the treatment group.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / mortality
-
Clinical Trials as Topic
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Drug Therapy, Combination
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Humans
-
Medroxyprogesterone / administration & dosage*
-
Medroxyprogesterone / adverse effects
-
Medroxyprogesterone / therapeutic use
-
Menopause
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Middle Aged
-
Prognosis
-
Random Allocation
-
Tamoxifen / administration & dosage*
-
Tamoxifen / adverse effects
-
Tamoxifen / therapeutic use
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Tamoxifen
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Medroxyprogesterone
-
Fluorouracil
-
Methotrexate